Solna, Sweden and Lugano, Switzerland, April 13, 2022 – AnaCardio, a Swedish clinical-stage biopharmaceutical company focussed on developing novel contractile agents with a unique mode-of-action […]

Lugano, Switzerland, February 3, 2023 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial […]

LUGANO, Switzerland and STOCKHOLM, Sweden – January 24, 2023 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over […]

Lugano, Switzerland, January 10, 2023 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a track record of over forty years of commercial […]

Lugano, Switzerland, January 9, 2023 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a track record of over forty years of commercial […]

Lugano, Switzerland, January 4, 2023 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial […]

Lugano, Switzerland, November 29, 2022 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial […]

CHIASSO, Switzerland and LUGANO, Switzerland – November 28, 2022 – Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution […]

Lugano, Switzerland, October 18, 2022 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a diversified pipeline of innovative oncology assets, announces that […]

Lugano, Switzerland, 21 September 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces that two […]